menu
    • menu

    Company profile for Mural Oncology

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mural Oncology plc is a clinical-stage oncology company with a focus on discovering and developing immunotherapies to improve the lives of patients with cancer. The company leverages its core competencies in immune cell modulation and protein engineering to develop a portfolio of novel investigational cytokine therapies. These therapies aim to address unmet needs in the treatment of various cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mural OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Waltham, MA 02451
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.muraloncology.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mural-oncology/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    XOMA Royalty Completes Acquisition Of Mural Oncology
    XOMA Royalty Completes Acquisition Of Mural Oncology

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200742/7281/en/XOMA-Royalty-Announces-Closing-of-Transaction-to-Acquire-Mural-Oncology-plc.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    Mural Oncology Announces Sanction Of The Scheme By The High Court
    Mural Oncology Announces Sanction Of The Scheme By The High Court

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3199385/0/en/Mural-Oncology-Announces-Sanction-of-the-Scheme-by-the-High-Court.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Mural Oncology Reveals Acquisition Cash Payment By XOMA Royalty
    Mural Oncology Reveals Acquisition Cash Payment By XOMA Royalty

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/26/3195159/0/en/Mural-Oncology-Announces-Final-Cash-Consideration-Payable-on-Closing-of-Acquisition-by-XOMA-Royalty.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    Mural Oncology Shareholders Approve Acquisition By XRA 5 Corp
    Mural Oncology Shareholders Approve Acquisition By XRA 5 Corp

    24 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/24/3173080/0/en/Mural-Oncology-Announces-that-Mural-Shareholders-Approve-the-Proposed-Acquisition-by-XRA-5-Corp-a-Wholly-Owned-Subsidiary-of-XOMA-Royalty.html

    GLOBENEWSWIRE
    24 Oct 2025
    Share Share
    Mural Oncology to be Acquired by XRA 5, XOMA Royalty Subsidiary
    Mural Oncology to be Acquired by XRA 5, XOMA Royalty Subsidiary

    20 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/20/3136413/7281/en/Mural-Oncology-Announces-Entry-into-Agreement-to-be-Acquired-by-XRA-5-Corp-a-wholly-owned-subsidiary-of-XOMA-Royalty-for-between-2-035-and-2-24-in-Cash-per-Share.html

    GLOBENEWSWIRE
    20 Aug 2025
    Share Share
    Mural Agrees to Xoma Buyout After Being Cornered
    Mural Agrees to Xoma Buyout After Being Cornered

    20 Aug 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/xoma-adds-fading-mural-oncology-portfolio-struggling-biotechs

    FIERCE BIOTECH
    20 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search